Back to search

Article

Prediction and treatment of skin adverse reactions related to inhibitors at immune checkpoints

2025-10-18

Abstract excerpt

<title>Abstract</title> <p> Immunotherapy has become the fifth major treatment modality in oncology, with immune checkpoint inhibitors (ICIs) being the most effective immunotherapeutic agents currently used in clinical practice. Although the majority of patients exhibit good tolerance to ICIs, a subset of patients may develop severe immune-related adverse events (irAEs) following treatment. In this study, we inc...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
2a9129f7-735c-5bdf-94bb-d4f72d7c559e
DOI
10.21203/rs.3.rs-7640849/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Prediction and treatment of skin adverse reactions related to inhibitors at immune checkpointsDOI 10.21203/rs.3.rs-7640849/v1
Biologic Treatment for Cutaneous Immune-Related Adverse Events in Cancer Patients Undergoing Immune-Checkpoint Therapy: A Retrospective ReviewSemantic proximity
Research progress on mechanisms and predictive biomarkers for immune-related adverse eventsSemantic proximity
The evolving landscape of immune‐related adverse events that follow immune checkpoint immunotherapy in cancer patientsSemantic proximity
Multiomics analysis reveals a Type III driven immune response in immunotherapy-induced toxicity in melanoma and identifies potential new therapeutic targetsSemantic proximity
Cutaneous immune-related adverse events are associated with longer overall survival in advanced cancer patients on immune checkpoint inhibitors: a multi-institutional cohort studySemantic proximity
Uncoupling Therapeutic Efficacy from Immune-Related Adverse Events in Immune Checkpoint BlockadeSemantic proximity
Pre-Existing Inflammatory Disease Predicts Cutaneous Immunotherapy Toxicity Development: A Multi-Institutional Cohort StudySemantic proximity
Construction and evaluation of clinical prediction model for immunotherapy-related adverse events and clinical benefit in cancer patients receiving immune checkpoint inhibitors based on serum cytokine levelsSemantic proximity
Revolutionizing Cancer Therapy: A Comprehensive Review of Immune Checkpoint InhibitorsSemantic proximity
Association of the CD4+ /CD8+ ratio with response to PD-1 inhibitor-based combination therapy and dermatologic toxicities in patients with advanced gastric and esophageal cancerSemantic proximity
Assessing the Pharmacological and Pharmacogenomic Data of PD-1/PD-L1 Inhibitors to Enhance Cancer Immunotherapy Outcomes in the Clinical SettingSemantic proximity
Development of an IFNγ response‐related signature for predicting the survival of cutaneous melanomaSemantic proximity
Select a neighboring publication to make it the new centre.